Aytu Biopharma AYTU
NASDAQ AYTU
$2.01 +0.05 (+2.55%)
As of: Oct 20, 2026 · 3:50 PM EDT

Aytu Biopharma (AYTU) Cash from Restructuring (2017)

Updated

Analysis

Aytu Biopharma (AYTU) Cash from Restructuring (2017) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,146.94 Bn 1,115.53 Bn 19.71 Bn
2 Johnson & Johnson 624.96 Bn 543.49 Bn 17.26 Bn
3 AbbVie 510.15 Bn 483.27 Bn 12.70 Bn
4 Merck 366.13 Bn 320.51 Bn 12.21 Bn
5 Novartis Ag 297.75 Bn 261.74 Bn 11.24 Bn
6 Astrazeneca 261.93 Bn 235.62 Bn 12.86 Bn
7 Amgen 236.51 Bn 191.91 Bn 7.24 Bn
8 Gilead Sciences 194.27 Bn 168.47 Bn 6.22 Bn
9 Pfizer 171.74 Bn 118.39 Bn 10.94 Bn
10 Aytu Biopharma 24.76 Mn -90.92 Mn 10.41 Mn
Historic Data

Historic Data

Download Data
DateValue
Mar 31, 2017 1,500.00
API Access

Aytu Biopharma Cash from Restructuring API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=cash-from-restructuring&ticker=AYTU&period=max&api_key=YOUR_API_KEY